Alamar Biosciences IPO Pop

Alamar Biosciences went public on April 17 after raising $191.25 million, and the stock jumped 33% in its Nasdaq debut. (bloomberg.com) The Fremont, California, company sold 11.25 million shares at $17 each after increasing the deal from 9.375 million shares marketed at $15 to $17. The stock trades on the Nasdaq Global Select Market under the ticker ALMR. (sec.gov) Alamar makes tools for proteomics, the measurement of proteins in blood and other samples to look for signs of disease. In its filing, the company said its NULISA platform is built to detect protein biomarkers at very low concentrations in non-invasive fluids such as blood. (sec.gov) That business sits in a corner of life sciences that sells both instruments and the disposable tests that run on them. Alamar told investors it had more than 100 instruments installed by December 31, 2025, with about half of 2025 revenue coming from consumables. (sec.gov) The company’s numbers gave investors a faster-growth story than many recent biotech listings. Revenue rose to $74.2 million in 2025 from $25.1 million in 2024, while net loss narrowed to $29.2 million from $47.1 million. (genomeweb.com, genomeweb.com) Alamar also told investors that all 10 of the top 10 biopharmaceutical companies by 2024 revenue were already customers. Its customer list includes research institutions, drugmakers, contract research organizations, and service labs. (sec.gov) The offering arrives after a long slump in new biotech issues, with investors favoring companies that already sell products instead of funding years of drug-development risk. Reuters, in a report republished by AOL, said demand for Alamar and Kailera showed buyers returning to parts of life sciences tied to diagnostics and tools. (aol.com) Alamar said the underwriters have a 30-day option to buy another 1,687,500 shares, which would increase proceeds if exercised. The banks leading the deal were J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel. (sec.gov) For now, the first-day pop puts Alamar in a small 2026 class of life-science listings that reached the market with real revenue, installed machines, and investors willing to pay up for both. (bloomberg.com, sec.gov)